Scientist/Senior Scientist, Antibody Engineering

Responsibilities

• Design and construct mutant phage libraries for antibody affinity maturation or humanization.
• Molecular cloning, mutagenesis, antibody gene assembly, and expression vector design.
• Express and purify recombinant antibodies using bacterial and mammalian expression systems.
• Perform binding, specific and in vitro functional assays.
• Collaborate with cross-functional project teams to advance lead antibodies through drug development stages.

Requirements

• Ph.D. in Biology, Biochemistry, Molecular Biology, or a related field.
• Hands-on experience with phage display technology for antibody engineering.
• Proficiency in molecular cloning, PCR, and mutagenesis.
• Experience with antibody expression and purification using E. coli, HEK293, and CHO systems.
• Strong analytical and problem-solving skills, with the ability to troubleshoot experiments independently.
• Excellent record-keeping, communication, and collaboration skills.
• Prioritization skills, with the ability to adapt to fast-paced and evolving research priorities.
• Track record of scientific productivity, including peer-reviewed publications, conference presentations, or patents.
• Additional experience in molecular biology and/or antibody discovery is highly desirable.

Qualifications

• Extensive hands-on experience in phage display, antibody engineering, and antibody characterization.

Skills

• Strong background in molecular biology.
• Experience with antibody engineering and characterization.
• Ability to perform molecular cloning, mutagenesis, and expression vector design.
• Knowledge of antibody expression and purification using various expression systems.
• Experience with in vitro functional assays and binding analysis.
• Collaborative skills to work with cross-functional project teams.

Benefits

• Competitive salaries ranging from $120,000 USD to $150,000 USD.

Pay

• California pay range: $120,000 USD - $150,000 USD.

Schedule

• Full-time position.

Company Information

Arrowhead Pharmaceuticals, Inc. (Nasdaq{{:}} ARWR) is a clinical stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.

Our corporate headquarters is in Pasadena, CA with research and development teams in Madison, WI & San Diego, CA, and a state of the art manufacturing facility in Verona, WI. Our employees are nimble, science-driven innovators who are collaborating to bring new therapies to patients in need.